Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy by Thomson, Iain G. et al.
Accepted Manuscript
Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing
oesophagectomy
Iain G. Thomson, Matthew P. Wallen, Adrian Hall, Rebekah Ferris, David C. Gotley,
Andrew P. Barbour, Andrew Lee, Janine Thomas, Bernard M. Smithers
PII: S1743-9191(18)30629-0
DOI: 10.1016/j.ijsu.2018.03.030
Reference: IJSU 4516
To appear in: International Journal of Surgery
Received Date: 7 November 2017
Revised Date: 19 February 2018
Accepted Date: 9 March 2018
Please cite this article as: Thomson IG, Wallen MP, Hall A, Ferris R, Gotley DC, Barbour AP, Lee A,
Thomas J, Smithers BM, Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing
oesophagectomy, International Journal of Surgery (2018), doi: 10.1016/j.ijsu.2018.03.030.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
TITLE PAGE: 
Title: 
NEOADJUVANT THERAPY REDUCES CARDIOPULMUNARY FUNCTION IN 
PATIENTS UNDEGOING OESOPHAGECTOMY 
 
Authors: 
Iain G. Thomson 1,2*, MBBS, FRACS, Matthew P. Wallen 3*, BExSS Hons, PhD, 
Adrian Hall 4, MBBS, FANZCA, FCICM, ACCAM , Rebekah Ferris 4, MBBS, 
FANZCA, David C. Gotley,1,2 MBBS, FRACS, PhD, Andrew P. Barbour1,2, MBBS, 
FRACS, PhD, Andrew Lee, MBBS1, Janine Thomas1, BSc, Bernard M. Smithers 1,2, 
MBBS, FRACS, FRCS  
Institutions and Affiliations: 
1Upper GastrointestinaI and Soft Tissue Unit, Princess Alexandra Hospital, 
Queensland, Australia 
2Discipline of Surgery, School of Medicine, The University of Queensland, Princess 
Alexandra Hospital, Queensland, Australia 
3Centre for Research on Exercise, Physical Activity and Health (CRExPAH), School 
of Human Movement and Nutrition Sciences, The University of Queensland, 
Queensland, Australia 
4Department of Anesthesia, Princess Alexandra Hospital, Queensland, Australia 
Correspondence to: Dr Iain Thomson (i.thomson@uq.edu.au) 
 
Corresponding Author: 
Dr. Iain G. Thomson 
Upper GI, Soft Tissue Unit, Discipline of Surgery, Princess Alexandra Hospital 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
199 Ipswich Road, Woolloongabba, Queensland, 4011, AUSTRALIA 
Telephone: +61 (07) 3176 5309 
Fax: +61 (07) 3176 5399 
Email: i.thomson@uq.edu.au 
 
Short Title / Running head:  
Reduced fitness after neoadjuvant therapy 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
1
Abstract 
 Neoadjuvant therapy (NAT) for oesophageal cancer may reduce 
cardiopulmonary function, assessed by cardiopulmonary exercise testing 
(CPEX). Impaired cardiopulmonary function is associated with mortality 
following esophagectomy. We sought to assess the impact of NAT on 
cardiopulmonary function using CPEX and assessing the clinical relevance of 
any change in particular if changes were associated with post-operative 
morbidity. 
 This was a prospective, cohort study of 40 patients in whom CPEX was 
performed before and after NAT. Thirty-eight patients underwent surgery and 
follow-up with perioperative outcomes measured. The primary variables 
derived from CPEX were the anaerobic threshold (AT) and peak oxygen 
uptake (V̇O2peak). 
There were significant reductions in the AT (pre-NAT: 12.4 ± 3.0 vs. post-NAT 
10.6 ± 2.0 mL.kg-1.min-1; p=0.001). This reduction was also evident for 
V̇O2peak (pre-NAT: 16.6 ± 3.6 vs. post-NAT 14.9 ± 3.7 mL.kg-1.min-1; 
p=0.004). The relative reduction in V̇O2peak was greater in chemotherapy 
patients who developed any peri-operative morbidity (p=0.04). For patients 
who underwent chemoradiotherapy, there was a significantly greater relative 
reduction in AT (p=0.03) for those who encountered a respiratory 
complication. 
 Cardiopulmonary function significantly declined as a result of NAT prior to 
oesophagectomy. The reduction in AT and V̇O2peak was similar in both the 
chemotherapy and chemoradiotherapy groups. 
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Keywords 
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Highlights 
- Neoadjuvant therapy reduces a patient’s anaerobic threshold by 14.5% 
- Neoadjuvant therapy reduces a patient’s peak oxygen uptake by 10.2% 
- The reduction in cardiopulmonary function is similar with neoadjuvant 
chemotherapy and neoadjuvant chemoradiotherapy  
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1.  Introduction 
 Oesophageal cancer is a significant cause of cancer related 
mortality(1). Surgical resection remains an integral component of curative 
treatment.  Advances in perioperative care, surgical technique and patient 
selection have seen mortality rates from specialised centres fall to rates of 1-
2% (2, 3). Morbidity remains a significant issue for patients recovering from 
oesophagectomy, with rates of significant morbidity reported to be 30-40%(4). 
In patients who present with resectable disease, there is a survival benefit 
with the addition neo-adjuvant treatment being chemotherapy or 
chemoradiotherapy (5). There is conflicting data as to whether NAT increases 
the risk of perioperative morbidity. A meta-analysis by Kumagai et al. 
examining morbidity and mortality associated with NAT and oesophageal 
cancer found no overall increase risk from NAT, however here was a higher 
risk of postoperative mortality from neoadjuvant  chemoradiotherapy in 
patients with oesophageal squamous cell carcinoma (SCC) (6). Other studies 
have found an increase in cardiopulmonary morbidity in patients receiving 
chemoradiotherapy (7, 8). With regard to cardiopulmonary reserve there is 
limited data on whether there is an objective decline in cardiopulmonary 
reserve in patients with oesophageal cancer who receive NAT.   
 
There is mounting evidence that a limited cardiopulmonary reserve is 
associated with increased risk of poor postoperative outcomes(9, 10).  
Assessment of perioperative risk has historically been conducted with a 
variety of tools. Cardiopulmonary exercise testing (CPEX) provides an 
objective assessment of a patient’s ability to tolerate the increased metabolic 
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demands and increase in oxygen consumption associated with surgery (11). 
There is evidence  that CPEX derived variables provide insight into assessing 
patient risk (12).  Peak oxygen uptake (V̇O2peak) and the anaerobic threshold 
(AT) are two measurements derived from CPEX. Both markers have 
demonstrated prognostic significance and may significantly impact the post-
operative course (12).  Jack and colleagues (2014) demonstrated a reduction 
in CPEX defined variables with preoperative chemotherapy (13). It remains 
unclear whether these changes were associated with increased perioperative 
morbidity following oesophagectomy.  The impact of CRT, as measured by 
CPEX, on patients undergoing oesophagectomy has  been presented in 
abstract form and to our knowledge, not previously been published.(14)  
 
The aim of this study was to measure CPEX derived variables in patients 
scheduled for an oesophagectomy before and after NAT. The primary 
objective was to assess for significant changes in the CPEX derived variables, 
anaerobic threshold (AT) and peak oxygen uptake (V̇O2peak). We also sought 
to assess if changes in these variables were associated with any difference in 
short-term surgical outcomes, in particular perioperative cardiorespiratory 
morbidity.  
 
2.  Materials and methods 
2.1 Patients 
This study was a single centre, prospective, cohort study.  Hospital Ethics 
approval and individual patient consent was obtained, (HREC/11/QPAH/332) 
and the study was registered on the Research Registry.  This study has been 
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reported in line with the STROCSS criteria (15).  Patients scheduled to 
undergo NAT prior to oesophagectomy between January 2011 and July 2015 
were invited to participate in the study. The inclusion criteria were the 
diagnosis of oesophageal cancer being treated with NAT followed by 
oesophagectomy and the completion of CPEX prior to and post NAT. The 
decision to offer NAT followed by oesophagectomy was made at the 
multidisciplinary team (MDT) meeting of the upper gastrointestinal unit. 
Patients were excluded from participation if they had a non-resectable tumor, 
chemotherapy and/or radiotherapy in the 30-days prior to screening, or unable 
to complete CPEX. 
 
All patients were staged with endoscopy and FDG - positron emission 
tomography with computed tomography. Endoscopic ultrasound and staging 
laparoscopy were used selectively.  Patients were restaged following NAT, 
with endoscopy and computed tomography scan of the chest and abdomen. 
NAT consisted of either neo-adjuvant chemotherapy or neo-adjuvant 
chemoradiotherapy. The standard choice of NAT during this period was 
enrollment in the DOCTOR trial (Appendix 1) which was a randomized phase 
II trial. Neoadjuvant treatment consisted of cisplatin, 5 fluorouracil alone, or 
combined with docetaxel. Treatment for Siewert III lesions requiring 
oesophagectomy was enrollment in the TOPGEAR trial.  This is a randomized 
phase III trial comparing 3 cycles of epirubicin, cisplatin and 5-fluorouracil 
(MAGIC protocol) (16) with and without concurrent radiation (Appendix 1). 
The standard radiotherapy regimen was 45 Gy radiation in 25 fractions 
(Appendix 1). Outside of the trials the decision for preoperative NAT was 
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made in the MDT based on the individual patient information.   Generally, 
NAT with radiation is preferred for squamous pathology or bulky disease.  
This is a MDT decision based on both diameter and length of the tumour or 
concerns that circumferential margin clearance may be difficult.  NAT without 
radiation preferred for less bulky node negative disease.  Oesophagectomy 
was scheduled for 4-6 weeks after completion of NAT. The surgery was 
performed at a single institution by one of four surgeons in the upper 
gastrointestinal surgical unit either as a thoracoscopic assisted 3-stage 
oesophagectomy or as an Ivor-Lewis oesophagectomy based on tumour 
location and surgeon preference. The techniques have been described in 
detail previously (17, 18).  Briefly, a thoracoscopic assisted oesophagectomy 
involves a thoracoscopic chest dissection followed by an open abdominal 
dissection and cervical anastomosis.  Some cases will have had a 
laparoscopic abdominal dissection rather than open based on surgeon 
preference.  The Ivor-Lewis oesophagectomy is an open abdominal dissection 
and thoracotomy in the majority.  Recently the unit has performed some cases 
with a laparoscopic and thoracoscopic Ivor-Lewis approach.  The decision on 
approach relates to the site of the primary cancer with the thoracoscopic three 
field approach our preferred and the Ivor-Lewis approach performed for 
carcinomas that involved a significant length of the gastric cardia.  
 
2.2 Study procedures 
Patients completed a CPEX at the hospital’s CPEX laboratory before NAT 
and was scheduled four weeks after the completion of the treatment.  Patient 
demographic information, co-morbidity, surgical, perioperative outcomes 
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including postoperative morbidity and mortality were collected prospectively. 
The complications were graded using the Clavien-Dindo classification(19) and  
were defined based on Esophagectomy Complication Consensus Group 
definitions (20).  Anastomotic leaks were classified using these definitions. 
Prior to 2014 all patients had routine contrast swallows on postoperative day 
5-7.  Since then clinical concerns are investigated with a combination of 
contrast swallow, CT scan with oral contrast and or endoscopy.  Radiologic 
evidence of a leak was recorded and graded(20).  
 
2.3 Cardiopulmonary exercise test 
CPEX was conducted according to the guidelines published in the American 
Heart Association 2010 Scientific Statement (21).  CPEX was performed on 
an upright cycle ergometer (Lode, Gronigen, NED). Following 1-minute of 
seated rest, participants maintained a constant cadence during a continuous 
incremental ramping protocol until volitional exhaustion. Gas exchange (VO2 
and VCO2) and ventilatory (VE) variables were measured using a breath-by-
breath metabolic system (Ultima Cardio O2, MCG Diagnostics, St. Paul, MN). 
Heart rate, oxygen saturation, non-invasive blood pressure and 12-lead 
electrocardiography were monitored throughout the test.  
 
The primary variables derived from CPEX were the AT and V̇O2peak; these 
were expressed in relative (mL.kg-1.min-1) terms.  These were chosen as 
primary measures as they have been previously demonstrated to be 
associated with postoperative outcomes(12).  The workload achieved at AT 
and V̇O2peak was recorded in watts (W). Ventilatory equivalents for oxygen 
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(VE/V̇O2) was used as a measure of ventilation required for metabolic demand 
at anaerobic threshold. The VE/V̇CO2 slope and oxygen uptake efficiency 
slope (OUES) were used as measures of the efficiency of ventilation with 
respect to carbon dioxide removal and oxygen uptake throughout the test.  
 
2.4 Statistical Analysis 
All continuous variables were assessed for normality using a Shapiro-Wilk test 
and are presented as mean ± standard deviation or median (Interquartile 
range). For categorical variables, the data was expressed as a count and 
percentage. Independent- t-tests and Mann-Whitney U-tests compared all 
variables between patients who received chemotherapy or 
chemoradiotherapy. Categorical variables were compared using Chi-square 
tests. Paired t-tests were also used to determine the change in variables 
derived from CPEX as a result of NAT. All statistical analyses were performed 
in a software package (SPSS, Version 22, IBM, New York, USA). Statistical 
significance was assumed if p<0.05.  The sample size was calculated for 
paired statistics comparing the change in relative AT. Published data has 
previously demonstrated NAT is associated with a reduction in relative AT of 
2.2 mL.kg-1.min-1, for this study, a standard deviation of 3.8 mL.kg-1.min-1 was 
used (13). Therefore, in order to obtain statistical power of 0.9 with statistical 
significance set at 0.05, a sample size of 34 was required. 
 
 
3.  Results 
3.1 Patient demographics 
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During the study period 387 patients with oesophageal cancer were managed 
with curative intent following presentation at the MDT. The management is 
outlined in figure 1.  Within this group 97 patients (25%) received neoadjuvant 
chemotherapy and 84 (22%) patients received neoadjuvant 
chemoradiotherapy. Within this group of patients 40 patients consented to 
participate in the study and completed CPEX testing before and after NAT. 
Two patients who received neo-adjuvant chemoradiotherapy did not progress 
to surgical resection; one due to disease progression and the other due to 
general performance status deterioration and an associated reduction in 
anaerobic threshold (pre NAT: 9.7 mL.kg-1.min-1; post NAT: 6.9 mL.kg-1.min-1) 
so that surgery was not considered appropriate. From the 38 patients who 
proceeded to oesophagectomy; 15 patients underwent an Ivor-Lewis 
resection, 12 with open abdomen and thoracotomy and 3 patients had a 
laparoscopic and thoracoscopic approach.  The remaining 23 patients had a 
thoracoscopic assisted 3-stage oesophagectomy, 2 of these had laparoscopic 
abdominal dissection and one case was converted to a trans-hiatal approach 
due to severe pleural adhesions (Table 1). The majority were male with a 
median age of 66. Sixteen (42%) patients were treated with neo-adjuvant 
chemoradiotherapy and the remaining 22 (58%) received neo-adjuvant 
chemotherapy. The median follow-up of all patients was 31 months (range 7-
69 months). (Table 1). 
 
3.2 Neo-adjuvant treatment 
Of the 22 (58%) patients receiving neo-adjuvant chemotherapy, 13 (33%) 
received 2 cycles of cisplatin and 5-fluorouracil (CF), 7 (18%) received 3 
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cycles of CF with docetaxel added to the second & third cycle as per the 
DOCTOR protocol, and 2 (5%) received 3 cycles of epirubicin and CF (ECF).  
Of the 16 undergoing neo-adjuvant chemoradiotherapy 13 (81%) were treated 
with 2 cycles of CF and 45 Gy in 25 fractions.  The remaining three patients 
(7.5%) had different regimens: One patient received 3 cycles CF with 
docetaxel added to the second & third cycles and 45 Gy in 25 fractions 
(DOCTOR protocol), one patient received 5 cycles carboplatin & paclitaxel 
with 41.4 Gy in 23 fractions (CROSS protocol), one patient received 3 cycles 
ECF with 45 Gy in 25 fractions (TOPGEAR protocol). Four patients in the neo-
adjuvant chemotherapy group had grade 3 complications during 
chemotherapy. Three required a dose reduction of docetaxel and the fourth 
patient developed a pulmonary embolus. There were no grade 3 or 4 
complications in the neoadjuvant chemoradiotherapy group. 
 
 
3.3 Effect of neo-adjuvant treatment on CPEX variables 
The impact of NAT on variables derived from CPEX is presented in Table 2. 
There was a significant reduction of 14.5% in relative AT (pre-NAT: 12.4 ± 3.0 
mL.kg-1.min-1; post-NAT: 10.6 ± 2.0 mL.kg-1.min-1; p=0.001) and 10.2% in 
V̇O2peak (pre-NAT: 16.6 ± 3.6 mL.kg-1.min-1; post-NAT: 14.9 ± 3.7 mL.kg-
1
.min-1; p=0.004). This significant decrease was also seen in the absolute 
value for AT and V̇O2peak. There was also a significant 24.2% reduction in 
the work rate required to achieve AT (pre-NAT: 69.3 ± 30.3 W; post-NAT: 52.5 
± 20.9 W; p=0.002) and 8.9% at V̇O2peak (pre-NAT: 101.6 ± 32.9 W; post-
NAT: 92.6 ± 31.4 W; p=0.03).  
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A separate analysis was also performed to determine the changes in CPEX 
variables based on treatment modality.  In patients receiving chemotherapy 
there was a 14.6% reduction in AT (pre NAT: 12.3 ± 3.3 mL.kg-1.min-1; post 
NAT: 10.5 ± 2.0 mL.kg-1.min-1; p=0.01) and 12% reduction in V̇O2peak (pre 
NAT: 16.6 ± 3.5 mL.kg-1.min-1; post NAT: 14.6 ± 3.1 mL.kg-1.min-1; p=0.02). 
Patients who received chemoradiotherapy also experienced a 14.4% 
reduction in AT (pre NAT: 12.5 ± 2.7 mL.kg-1.min-1; post NAT: 10.7 ± 2.0 
mL.kg-1.min-1; p=0.04). Although there was a 7.3% decrease in V̇O2peak (pre 
NAT: 16.5 ± 3.7 mL.kg-1.min-1; post NAT: 15.3 ± 3.3 mL.kg-1.min-1; p=0.12). 
There was no significant between-group decrease in AT and V̇O2peak based 
on therapy type. However, there was a significant between-group increase in 
the VE/V̇CO2 slope for patients who underwent chemoradiotherapy (pre NAT: 
26.5; post NAT: 30.0; p=0.01), compared to those who received 
chemotherapy alone (pre NAT: 26.5; post NAT: 26.0; p=0.62) [F(1,37) = 6.96, 
p=0.01, partial η2 = 0.16]. No other CPEX variables were significantly different 
based on the type of treatment used. 
 
3.4 Perioperative outcomes & morbidity 
There was no in hospital or 30-day mortality. The median length of stay was 
13 days. One patient died on postoperative day 77, due to disease 
progression (Table 2). Morbidity was seen in 28 patients (74%), respiratory 
morbidity was most common with 14 patients (37%) having 18 events.  There 
were 7 patients (18%) with Clavien-Dindo grade 3/4 morbidity. One (3%) 
returned to theatre for drainage of an anastomotic leak and one (3%) returned 
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to theatre and ICU for treatment of empyema secondary arising from 
pneumonia. Two patients (5%), required re-intubation due to ARDS while in 
ICU.  Three patients required radiologic insertion of chest drains for pleural 
effusions. The cardiac morbidity, seen in 13 (34%) patients, were Clavien-
Dindo grade 2 arrhythmias. There were 5 (13%) patients with anastomotic 
leak of which, 4 (11%) were grade 1, managed with dietary modification 
(Table 3). 
 
 
3.5 Relationship of CPEX variables and morbidity 
Analysis of the entire cohort demonstrated no statistical difference in the 
relative change in CPEX variables following NAT between those who did or 
did not develop peri-operative complications. However, analyzing patients 
who received preoperative chemotherapy, there was a significant relative 
reduction in V̇O2peak for patients who developed peri-operative complications 
(-23.2 ± 22.98%) compared to those who did not (2.2 ± 
25.4%)(p=0.04)(Figure 3).  
 
For those patients who underwent chemoradiotherapy, there was no 
significant difference in CPEX variables for patients who did or did not 
develop peri-operative complications. However, those patients who developed 
a respiratory complication had a significantly greater relative reduction in AT (-
20.5 ± 15.9%) compared to patients without any respiratory complications 
(2.55 ± 19.8%)(Figure 4).  
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4.  Discussion 
This study aimed to assess the change in CPEX derived variables in patients 
undergoing NAT prior to oesophagectomy.  The results presented 
demonstrate that NAT significantly reduces the measures of cardiopulmonary 
function derived from CPEX. We observed a 14.5% and 10.2% decline in 
relative AT and V̇O2peak, respectively. For patients who received neo-
adjuvant chemotherapy, the decline in V̇O2peak was associated with peri-
operative complications and anastomotic leaks. For patients who received 
neo-adjuvant chemoradiotherapy the decline in AT was associated with 
respiratory complications.  
 
There is evidence demonstrating a survival benefit from the use of NAT in 
oesophageal cancer (5). However, the ideal combinations of chemotherapy 
and radiation are still examined and debated. There remains a significant 
incidence of morbidity following oesophagectomy (4). It is postulated that NAT 
has a direct influence on the type and severity of perioperative morbidity. Until 
recently, the impact of these treatments on a patient’s physical fitness 
remained unclear. Jack and colleagues demonstrated a reduction in physical 
fitness in 39 patients undergoing neo-adjuvant chemotherapy with a 15% 
reduction in AT (mean difference 2.2 mL.kg-1.min-1) and a 12% reduction in 
V̇O2peak (mean difference 2.5 mL.kg-1.min-1) (13). Similarly, a recent 
investigation also demonstrated a 17.3% reduction in AT (mean difference 2.4 
mL.kg-1.min-1) in 30 patients receiving neo-adjuvant chemotherapy (22). 
These reductions were similar compared to the findings presented here, with 
reductions in AT of 9.1% (mean difference 1.9 mL.kg-1.min-1) and at peak 
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exercise of 16.3% (mean difference 2.0 mL.kg-1.min-1) for our cohort of 
patients who received chemotherapy.  
 
The only study assessing the impact of neoadjuvant chemoradiotherapy  
reported a 10.5 % reduction in AT in 17 patients receiving neo-adjuvant 
chemoradiotherapy, which is similar to the 11.4% (mean difference 1.8 mL.kg-
1
.min-1) reduction in AT seen in our cohort of patients who received 
chemoradiotherapy (14).  The impact of CRT  in a cohort of patients who had 
rectal cancer as measured by CPEX reported a similar effect on the CPEX 
variables in 25 patients,  demonstrating a mean reduction in AT and peak 
exercise of 1.5 and 1.4 mL.kg-1.min-1, respectively (23). Our data and all of 
these studies demonstrate a consistent and similar negative impact of NAT on 
patient cardiopulmonary reserve (AT ranging from 9.1%-17.3%; V̇O2peak 
ranging from 12%-16.3%) 
 
There are concerns that neoadjuvant chemoradiotherapy may increase 
perioperative complications(7, 8), and recent results demonstrating increased 
mortality in the first 12 months(24).   Few studies have examined the change 
in CPEX variables and the association with morbidity after CRT. We have 
demonstrated both neo-adjuvant chemotherapy and chemoradiotherapy have 
a similar impact on CPEX variables. The only significant between-group 
difference was the increase in the VE/V̇CO2 slope for patients who were 
treated with chemoradiotherapy. Patients receiving chemoradiotherapy 
experienced a 15% increase in the VE/V̇CO2 slope, in comparison to a -0.5% 
decrease for those who underwent chemotherapy. An elevated VE/V̇CO2 
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reflects ventilation-perfusion mismatching and is associated with unfavorable 
cardiopulmonary complications, (23, 24) the radiation dose to surrounding 
lung may be an explanation for this change and has been demonstrated to be 
related to respiratory complications(25).  However, this was not predictive of 
post-operative morbidity or mortality. The decline in AT in those receiving 
neoadjuvant chemoradiotherapy was not associated with a significant 
increase risk of overall complications or mortality.  The decline in AT in those 
receiving neoadjuvant chemoradiotherapy however was associated with 
respiratory complications. 
 
The majority of patients considered to be suitable for oesophagectomy and 
NAT using a traditional medical assessment are likely to have an acceptable 
CPEX result pretreatment. The information obtained from CPEX related to a 
patient’s potential cardiopulmonary reserve and provides additional 
quantification of post-operative risk, which is more likely to be relevant to 
those clinically borderline patients. The exact measurement or value that 
provides the best information in this select population is not clear (26). Jack 
and colleagues determined an optimal cutoff value of the AT to be ≥ 13.9 
mL.kg-1.min-1 for post-oesophagectomy survival following NAT (13).  Data 
from non oesophagectomy series suggests that an AT<11 mL.kg-1.min-1 is 
associated with increased perioperative risk (10). Our median AT post NAT 
was 10.6 mL.kg-1.min-1 leaving 50% of our patients “not fit” or at least at 
increased risk if they had an oesophagectomy. There is likely no absolute 
cutoff point or ‘magic number’; rather the information derived from CPEX 
needs to be integrated into the comprehensive peri-operative assessment in 
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selected patients. The demonstrated reduction in cardiorespiratory fitness 
seen with NAT may have significant implications for patients bordering the 
‘high-risk’ stratification during assessment.  Knowledge of the potential risk for 
developing complications in the post-operative phase may then outweigh the 
potential benefits seen with NAT.  
 
The role of exercise training or ‘prehabilitation’ is an expanding area of 
research. Improving outcomes with an intervention such as exercise training 
has a strong appeal and CPEX provides an ideal method for quantifying 
changes. Patients who are undergoing NAT for esophageal cancer are 
commonly scheduled for surgery 4-6 weeks following the completion of NAT. 
This scheduling provides an opportunity to improve cardiorespiratory fitness, 
and potentially reduce morbidity and improve recovery from surgery. There is 
uncertainty as to whether such an intervention will result in improved clinical 
outcomes. A systematic review of exercise training in elective abdominal and 
cardiothoracic surgery examined 10 randomized-controlled trials (27). The 
authors concluded that exercise training is safe, feasible and improves 
several health-related physical fitness outcomes in this population (27). The 
improvement in clinical outcomes was less clear with one cardiac surgery 
study showing a reduced ICU and hospital stay with the exercise program.  
 
The anastomotic leak rate in this study was 13% overall which may at first 
appear high, however the clinically more relevant grade 3 anastomotic leak 
rate was 2.6%. The overall rate reflects accurate reporting with accepted 
definitions and a majority of patients with a cervical anastomosis. The leak 
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rate reported in this series  is comparable to those from large single centre 
MIE series reporting a 5% grade 3 leak rate (28), and an overall rate of 12% 
in a large series with cervical anastomosis(29).  It compares favourably with 
reported rates in recent randomized trials investigating NAT in esophageal 
cancer of 9 - 30%(24, 30)    
 
A limitation of this study is the small sample size which makes difficult the 
comparison of the CPEX variables following NAT with clinical outcomes, 
however our primary objective was to quantify the reduction in CPEX 
variables for which the study is adequately powered.  Minor variations in the 
neo-adjuvant treatments used in our study reflect current practice and our 
involvement in ongoing clinical trials.  The variation in surgical technique in 
the study is another source of bias which may have an impact on the short 
term clinical outcomes.  Minimally invasive techniques were applied in 25 
(68%) of resected patients, this may be a confounder particularly with regard 
to respiratory complications.   We feel these differences are unlikely to have a 
significant impact on the primary outcome measures. Another limitation is the 
fact that only 40 of 181 possible patients were recruited over the study period.  
We have analysed the group who did not participate and there were no major 
differences with regard to comorbidities or postoperative outcomes compared 
to the study population (data not shown).  Within this group 15 patients 
underwent a CPEX prior to NAT, with a median AT of 11.3mL.kg-1.min-1 which 
would suggest those patients in the study had similar cardiorespiratory fitness 
to those not included. A strength of our study is the use of internationally 
recognized definitions of complications and a grading system which will be 
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allow accurate comparison of our findings with other research in this 
population (20).  
 
The current study demonstrates significant reduction in objective measures of 
cardiopulmonary reserve associated with NAT prior to oesophagectomy. This 
impact is demonstrated for both neo-adjuvant chemotherapy and neo-
adjuvant chemoradiotherapy. The adverse effect on clinical outcomes is 
uncertain and more investigation is required.  The negative effect of NAT 
should be considered in the perioperative management of those patients who 
have a reduced cardiopulmonary reserve. Additionally, the role of exercise 
training to improve or restore cardiopulmonary reserve prior to surgery should 
be investigated.  
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Figure 1. Patient recruitment 
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Figure 2. Neoadjuvant treatment outline 
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Table 1. Patient demographics and clinical characteristics.  
Variables a Chemotherapy 
(n=22) 
Chemoradiotherapy 
(n=16) 
Overall (n=38) 
Age 65 (15.3) 67.5  (7.3) 66 (10.5) 
Sex: male (n, %) 19 (86.4%) 12 (75%) 31 (81.60%) 
Body mass index (kg/m2) 29.56 ± 4.22 28.56 ± 3.38 29.17 ± 3.87 
Clinical T Stage (n, %)    
 T2 5 (22.7%) 9 (56.3%) 14 (36.8%) 
 T3 17 (77.3%) 7 (43.8%) 24 (63.2%) 
Clinical N Stage (n, %)    
 N0 16 (72.7%) 8 (50%) 24 (63.2%) 
 N1 6 (27.3%) 8 (50%) 14 (36.8%) 
ASA (n, %)    
 1  3 (13.6%) 0   3 (7.9%) 
 2 10 (45.5%) 11 (68.8%) 21 (55.3%) 
 3 9 (40.9%) 5 (31.3%) 14 (36.8%) 
Surgical resection (n, %)    
 Ivor Lewis 8 (36.4%) 7 (43.8%) 15 (39.5%) 
 Thoracoscopic 3 stage 14 (63.6%) 9 (56.3%) 23 (60.5%) 
Days from post CPEX to 
surgery 
15.0 (14.0) 16.8 (8.7) 22 (11.3) 
Follow up (months) 33.5 (7-69)) 30.5 (8-65) 31 (7-69) 
a Continuous variables as mean ± SD or median (interquartile range). Categorical data as 
number (%). 
 
ASA = American Society of Anesthesiologists; CPEX = cardiopulmonary exercise test  
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Table 2. Differences in cardiopulmonary exercise testing variables before and after neoadjuvant 
therapy.  
Variables a Before therapy 
(n=40) 
After therapy 
(n=40) 
Mean difference (95% CI) P-value 
Outcomes at anaerobic threshold 
 Work rate (W) 69.3 ± 30.3 52.5 ± 20.9 16.8 (6.8 to 26.7) 0.002 
 V̇O2 (mL.kg-1.min-1) 12.4 ± 3.0 10.6 ± 2.0 1.9 (0.8 to 2.9) 0.001 
 V̇O2 (mL.min-1) 1053.6 ± 330.1 858.9 ± 207.6 194.7 (105.2 to 284.2) <0.001 
Outcomes at peak exercise 
 Work rate (W) 101.6 ± 32.9 92.6 ± 31.4 9.15 (0.9 to 17.4) 0.030 
 V̇O2 (mL.kg-1.min-1) 16.6 ± 3.6 14.9 ± 3.7 1.6 (0.5 to 2.7) 0.004 
 V̇O2 (mL.min-1) 1402.5 ± 397.1 1224.0 ± 357.6 178.5 (84.7 to 272.2) <0.001 
 VE/V̇CO2 slope 26.5 ± 3.6 27.7 ± 5.1 -1.2 (-2.9 to 0.5) 0.170 
 OUES 2.0 ± 0.5 1.7 ± 0.4 0.3 (0.1 to 0.4) <0.001 
a Continuous variables as mean ± SD. 
 
V̇O2 = oxygen uptake; VE/V̇CO2 = ventilatory equivalents for carbon dioxide; OUES = oxygen 
uptake efficiency slope 
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Table 3. Patient surgical and perioperative outcomes.  
Variables a Chemotherapy 
(n=22) 
Chemoradiotherapy 
(n=16) 
Overall (n=38) 
30-day in-hospital mortality (n, 
%) 
0  0  0  
90-day mortality (n, %) 1 (4.5%) 0  1 (2.6%) 
All peri-operative morbidity (n, 
%) 
16 (72.7%) 12 (75%) 28 (73.7%) 
Clavien-Dindo ≥ Grade 3  3 (13.6%) 4 (25%) 7(18.4%) 
Return to operating theatre or 
ICU (n, %) 
1 (4.5%) 1 (6.2%) 2 (5.3%) 
Anastomotic leak (n %) 5 (22.7%) 0  5 (13.2%) 
 Grade 1 (n %) 4 (18.2%) 0  4 (10.5%) 
 Grade 2 (n %) 0  0  0  
 Grade 3 (n %) 1 (4.5%) 0  1 (2.6%) 
Respiratory morbidity b  7 (31.8%) 7 (43.8%) 14 (36.8%) 
 Pneumonia (n) 6 (27.3%) 7 (43.8%) 13 (34.2%) 
 Effusion (n) 0  3 (18.8%) 3 (7.9%) 
 Respiratory failure/ARDS (n) 2 (9.1%) 0  2 (5.3%) 
Cardiac morbidity (n %) 7 (31.8%) 6 (37.5%) 13 (34.2%) 
 Myocardial ischemia (n %) 0  0  0  
 Arrhythmia (n %) 7 (31.8%) 6 (37.5%) 13 (34.2%) 
a
 Continuous variables as median (interquartile range). Categorical data as number (%). 
 
b There were 14 patients with respiratory morbidity, with a total of 18 complications. 
 
ARDS = acute respiratory distress syndrome 
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Figure 3. Change in relative V̇O2 at peak exercise (mL.kg-1.min-1) before and 
after chemotherapy, divided into patients who did (Yes) or did not (No) 
develop one or more peri-operative complications. 
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Figure 4. Change in V̇O2 at AT (mL.kg-1.min-1) before and after 
chemoradiotherapy, divided into patients who did (Yes) or did not (No) 
develop a respiratory complication following surgery. 
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Highlights 
- Neoadjuvant therapy reduces a patient’s anaerobic threshold (AT) by 14.5% 
- Neoadjuvant therapy reduces a patient’s peak oxygen uptake (V̇O2peak) by 10.2% 
- The reduction in cardiopulmonary function is similar with neoadjuvant 
chemotherapy and neoadjuvant chemoradiotherapy 
